BioMarin Pharmaceutical (BMRN) Expected to Announce Earnings on Wednesday

BioMarin Pharmaceutical (NASDAQ:BMRN) is expected to be posting its quarterly earnings results after the market closes on Wednesday, February 19th. Analysts expect BioMarin Pharmaceutical to post earnings of $0.54 per share and revenue of $711.05 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN stock opened at $63.55 on Wednesday. BioMarin Pharmaceutical has a 12 month low of $60.63 and a 12 month high of $94.85. The firm has a market capitalization of $12.11 billion, a PE ratio of 38.05, a price-to-earnings-growth ratio of 0.57 and a beta of 0.28. The firm has a fifty day simple moving average of $64.94 and a two-hundred day simple moving average of $71.93. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on BMRN shares. StockNews.com upgraded shares of BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Tuesday. William Blair downgraded BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 30th. Evercore ISI cut their target price on BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 30th. Canaccord Genuity Group decreased their price target on BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating for the company in a report on Wednesday, October 30th. Finally, Citigroup dropped their price objective on BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. Seven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $94.20.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.